October 15, 2019 -- InvestorsHub NewsWire -- via BioResearch Alert's Blog
- About: Puration, Inc. (PURA), Includes: ACB, CGC, NOUV
Originally Published on SeekingAlpha.com/PURA
- Canada 2.0 CBD legalization goes into effect October 17, 2019
- Of 650 Chefs surveyed at the American Culinary Federation, 75% said cannabis infused foods will be the hottest trend starting in 2019 and beverages are at the top of the list.
- PURA has big head start in CBD infused beverages and offers CBD Sports Water, CBD Tea, and now CBD Coffee.
- Coca Cola’s interest in CBD infused Coca Cola confirms PURA CBD beverage growth targets.
- PURA Reports 87% Revenue Growth Breaking $1 Million In First 6 Months Of 2019 from Cannabis Infused beverages and confirms $4 million 2019 sales target.
- Goldman reports $0.35 PURA Target in New Analyst Research Report
Puration, Inc. (PURA) today announced an anticipated sales boost from Cannabis 2.0 – the legalization of cannabis infused edibles and beverages in Canada going into effect later this week on October 17th. PURA management has observed a movement in Canada toward CBD infused sports nutrition beverages. Both Aurora Cannabis (OTC:ACB) and Canopy Growth (OTC:CGC) have made recent moves into the sports nutrition beverage sector. Aurora has entered into a deal with the UFC and Canopy acquired sports beverage maker BioSteel Sports Nutrition. PURA management has recently reported Canadian inquiries regarding various contractual opportunities with PURA’s leading sports nutrition beverage EVERx CBD Sport Water. While other companies are looking to get into the $50 billion sports nutrition sector, PURA has over two years of experience producing and selling its EVERx product.
Multiple surveys indicate consumers are eager to purchase edibles and beverages. Specifically, a study conducted by research firm Deloitte reported that over half of surveyed respondents were likely to try cannabis-edibles, and 37% were likely to try cannabis-beverages. PURA commissioned its own survey on the cannabis beverage sector that is available for review online.
In addition to the inquiries from Canada about PURA’s EVERx reported by management, PURA has a ready partner of its own as an entry into the Canada 2.0 market opportunity. The CEO of PURA, Brian Shibley, is also the CEO of PURA spinoff, Nouveau (OTCPK:NOUV) a cannabis cultivator with a licensed operation in Canada. NOUV’s Canadian operation is small today, but still gives PURA access to Canada 2.0 while evaluating other suitors that may give PURA accelerated access to the Canada 2.0 market.
PURA has reported over $1 million in CBD beverage sales in the first six months of 2019 after reporting approximately $1 million in sales for all of 2018. On top of its ongoing sales, PURA has signed a new European distribution agreement anticipated to generate $4 million annually with a first shipment scheduled later this month. PURA has also recently announced a new distribution agreement in Latin America. PURA offers CBD Sports Water, CBD Tea, and recently announced a new line of CBD coffee.
Goldman Small Cap Research CBD beverage industry was conducted in conjunction with the PURA's initiative to launch new CBD Infused beer, coffee and tea beverages. Goldman summarizes the results with a confirmation of the $0.35 Price target for the shares of PURA and a Speculative Buy recommendation issued on September 25, 2019 (see link below to Sep 25 Analyst Report).
"Great Entry Point for Emerging Leader. With the stock basing at current levels, even a modest series of news and milestone events should drive the stock toward our price target. Moreover, with strong seasonality in the current quarter, and new markets just opened, PURA has the wind at its back."
"Key Numbers: When asked in order of preference what CBD-infused beverage they would buy, 77 or 31% said tea and 74 or 30% said water. As a provider of water and tea, PURA leadership certainly is providing consumers the most popular categories of CBD-infused beverages which bodes very well for future sales and market share growth."
"The Trend is PURA's Friend: While CBD oils remain the most popular source of CBD products, the data and responses indicate that oils, vapes, and tinctures usage may be swapped on an ever-increasing scale, for edibles and beverages. We expect that they will eventually overtake these product categories which will be a boon to PURA."
"Conclusion: While the interim CBD user survey results were favorable for PURA, the final results were overwhelmingly positive for the Company's future. There are a number of surprising results from this survey, which had a final identifiable respondent tally of 246 participants, as compared with our 85 identifiable responses when we issued interim results. The bottom line is that these results affirm to us that PURA is well-positioned to lead the CBD-infused beverage market and we reiterate our $0.35 price target."
Tomorrow, On Friday, October 11, 2019, PURA will publish an update on the launch of TranquiliTeaCBD and a new coffee infused with CBD in addition to including a progress update on the company's progress toward its 2019 $4 millionsales milestone.
PURA has reported over $1 million in CBD beverage sales in the first six months of 2019 after reporting approximately $1 million in sales for all of 2018. On top of its ongoing sales, PURA has signed a new European distribution agreement anticipated to generate $4 million annually with a first shipment scheduled later this month.
To see the full final CBD Beverage industry survey results, follow the link below:
CBD Beverage Industry Results – October 10, 2019
To see the original full Analyst Report, follow the link below:
PURAITON, Inc. Research Analyst Report – September 25, 2019
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.